Division of Rheumatology, Department of Internal Medicine, Uludağ Medical Faculty, Uludağ University, Bursa, Turkey.
Mod Rheumatol. 2012 Jun;22(3):463-6. doi: 10.1007/s10165-011-0507-7. Epub 2011 Aug 17.
Findings of several reports suggest that rituximab, a chimeric monoclonal anti-CD20 antibody causing B-lymphocyte depletion, might represent a treatment option for people with granulomatosis with polyangiitis (GPA) (former Wegener's granulomatosis). This study presents the results of rituximab treatment in two patients with treatment-refractory GPA. First patient received rituximab for a granulomatous posterior orbital mass lesion, and eye symptoms were resolved after three courses of treatment. The second patient had eye and paranasal sinus involvement and benefited from two courses of rituximab treatment, with significant clinical improvement. Rituximab may represent an effective novel treatment for remission induction in GPA.
几项报告的结果表明，利妥昔单抗（一种嵌合型单克隆抗 CD20 抗体，可导致 B 淋巴细胞耗竭）可能是治疗肉芽肿性多血管炎（GPA）（以前称为韦格纳肉芽肿病）患者的一种治疗选择。本研究介绍了利妥昔单抗治疗 2 例难治性 GPA 患者的结果。第一例患者因肉芽肿性眶后肿块病变接受利妥昔单抗治疗，经过 3 个疗程的治疗后眼部症状得到缓解。第二例患者眼部和鼻旁窦受累，接受了 2 个疗程的利妥昔单抗治疗后，临床症状显著改善。利妥昔单抗可能是诱导 GPA 缓解的一种有效新型治疗方法。
